Acute ischemic stroke
Conditions
Brief summary
Efficacy: Proportion of participants with no or minimal symptoms at 90 days., Safety: Incidence of symptomatic intracranial hemorrhage, defined as local or remote parenchymal hemorrhage type 2, subarachnoid hemorrhage, and or intraventricular hemorrhage within 36 hours post-randomization, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline (the closest collection before administration of the study treatment), or from the lowest NIHSS value between baseline and 24 hours, or leading to death.
Interventions
DRUGJX10
DRUGJx10 placebo drug product is prepared as a sterile
DRUGlyophilized white to light yellow cake or powder for infusion.
Sponsors
Corxel Pharmaceuticals Co. Ltd.
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Efficacy: Proportion of participants with no or minimal symptoms at 90 days., Safety: Incidence of symptomatic intracranial hemorrhage, defined as local or remote parenchymal hemorrhage type 2, subarachnoid hemorrhage, and or intraventricular hemorrhage within 36 hours post-randomization, combined with a neurological deterioration of 4 points or more on the NIHSS from baseline (the closest collection before administration of the study treatment), or from the lowest NIHSS value between baseline and 24 hours, or leading to death. | — |
Countries
Belgium, Bulgaria, Finland, France, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Poland, Portugal, Spain
Outcome results
None listed